Kissei tells doctors in Japan to stop starting new patients on Tavneos after reported deaths and liver injury cases
The facts
- Kissei Pharmaceutical said 20 fatal cases have been reported in Japan among patients who took Tavneos.
- Kissei told healthcare professionals to stop prescribing Tavneos to new patients in Japan and to reassess treatment for current patients because of severe liver dysfunction risk.
- Kissei said Tavneos has been used by about 8,500 patients in Japan since its launch there in June 2022.
- Postmarketing reports in Japan included 22 cases of vanishing bile duct syndrome among Tavneos users, and 13 of those cases were fatal.
- Tavneos is used in Japan to treat ANCA-associated vasculitis, including microscopic polyangiitis and granulomatosis with polyangiitis.
- Kissei and Amgen said not all of the reported deaths have been confirmed as caused by Tavneos.
- The reports in Japan come after the U.S. FDA warned in March about severe liver injury in patients taking Tavneos and later proposed withdrawing the drug's U.S. approval.
Context
What is Tavneos used for?
Tavneos is approved to treat ANCA-associated vasculitis, including microscopic polyangiitis and granulomatosis with polyangiitis, rare autoimmune diseases that inflame blood vessels AsiaOne,BERNAMA,Kyodo News+.
What action has Kissei taken in Japan?
Kissei sent a notice to healthcare professionals telling them not to start new patients on Tavneos and to evaluate whether current patients should remain on treatment because of the risk of severe liver dysfunction WSJ,Straits Times,Orange Actualités.
Is it confirmed that Tavneos caused all 20 deaths?
No. Multiple reports say Kissei and Amgen stated that a causal link has not been established for all of the reported deaths, even as the companies disclosed the cases and warned about liver-related risks Straits Times,Witness,AsiaOne.
Common ground, and where they split
- Common ground
- Reported fatal cases, severe liver dysfunction warnings, and fatal postmarketing reports in Japan are serious enough to justify stopping Tavneos for new patients and reassessing current treatment, even as causation for every death remains unconfirmed.
- Where Left and Right split
- Less a disagreement than a question of emphasis: patient safety requiring swift action to keep a risky drug off the market, versus evidentiary caution about not treating every reported death as confirmed to have been caused by Tavneos.
How left and right read it
The most important facts are that 20 fatal cases were reported in Japan among patients who took Tavneos, and Kissei told healthcare professionals to stop prescribing it to new patients and reassess current treatment because of severe liver dysfunction risk. With 22 postmarketing reports of vanishing bile duct syndrome, 13 fatal, and a U.S. FDA warning followed by a proposal to withdraw U.S. approval, this is a reminder that patient safety has to come before keeping a drug on the market.
Twenty reported fatal cases in Japan, a directive to stop prescribing Tavneos to new patients, and postmarketing reports that include fatal cases of vanishing bile duct syndrome are exactly the kind of warning signs that call for caution and serious reassessment. At the same time, the fact that Kissei and Amgen say not all reported deaths have been confirmed as caused by Tavneos underscores the need to follow the evidence carefully rather than jump past what is established.
The receipts — 27 sources
Other coverage (27)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.